Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer-Reference-Cited by-同舟云学术

Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer

Published:2013-11-12 Issue:3 Volume:142 Page:603-609
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Hurvitz Sara A.,Lalla Deepa,Crosby Ross D.,Mathias Susan D.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-013-2734-4.pdf

Reference15 articles.

1. Bailey CH, Jameson G, Sima C, Fleck S, White E, Von Hoff DD, Weiss GJ (2012) Progression-free survival decreases with each subsequent therapy in patients presenting for phase I clinical trials. J Cancer 3:7–13

2. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24(18):2715–2722

3. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE, Doorduijn JK, Sydes MR, Kvalheim G (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol 21(21):3918–3927

4. Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, Shepherd L, Hines JD, Schiffer CA, Larson RA (2008) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105(1):49–53

5. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Random Forest-Based Approach for Integrating Blood Profile in Metastatic Breast Cancer Classification;2024 International Conference on Science, Engineering and Business for Driving Sustainable Development Goals (SEB4SDG);2024-04-02

2. Updated evidence of primary tumor resection in stage IV breast cancer: a systematic review and meta-analysis;Journal of Cancer Metastasis and Treatment;2023-12-27

Overexpression of MTFR2 Predicts Poor Prognosis of Breast Cancer

;Cancer Management and Research;2020-11

4. Stated preferences for relapsed or refractory mantle cell lymphoma treatments in Sweden and Germany;Future Oncology;2020-05

5. The Evolution of Clinical Trials in Metastatic Breast Cancer: Design Features and Endpoints That Matter;American Society of Clinical Oncology Educational Book;2020-05